Pharma Firm Digital Vision Under DCGI Scanner For Allegedly Selling Contaminated Cough Syrup

The probe was started last week when CDSCO received a complaint from the department of pediatrics at the PGI Chandigarh, alleging that a two-year-old child suffered acute renal (kidney) failure after consuming the 'Cofset AT' cough syrup.

Representative Image

The Drugs Controller General of India (DCGI) has initiated a probe against Himachal Pradesh-based Pharma firm Digital Vision for allegedly selling a contaminated cough syrup under the brand name 'Cofset AT', that caused kidney failure in a two-year-old child. According to the reports, the US Food and Drug Administration (FDA) has alleged that the cough syrup was contaminated with Diethylene Glycol (DEG), a chemical known for causing kidney failure and neurological toxicity. The probe was started last week when India’s apex regulator, the Central Drugs Standard Control Organisation (CDSCO) received a complaint from the department of pediatrics at the Postgraduate Institute of Medical Education and Research Chandigarh, alleging that a two-year-old child suffered acute renal (kidney) failure after consuming the cough syrup. Following this, the CDSCO authorities ordered a nationwide halt of the syrup's supply, sales and distribution till the investigation is complete. It also asked the Himachal Pradesh’s drug controller to take quick and necessary action, check the samples of the drug across the country and initiate a probe into the matter. The Company Digital vision is a Kala Amb based Company established in the year 2009. It is a Pharma Franchise Company that is headed by the owner Parshotam Goyal and Konic Goyal. As per its description, the firm offers a wide range of pharmaceuticals medicines and protein powders. Earlier this year in February as well, the firm Digital Vision was booked by the Himachal government for selling another contaminated cough syrup 'ColdBest-PC' which allegedly led to the death of at least ten children.